SAGE PRO

Home / Research / Emcure Pharmaceuticals Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Emcure Pharmaceuticals Limited — Q2 FY27 Results Analysis

Revenue grew 24.3% YoY

Published · Quarter Q2 FY27 · EMCURE

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Q2 consolidated operating revenue

Q2 FY2622,698 INR million
Q2 FY2728,205 INR million

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e68bb867-ce7b-4907-b685-2f92b852319e.pdf

CHART 2

Q2 EBITDA

Q2 FY264,391 INR million
Q2 FY275,748 INR million

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e68bb867-ce7b-4907-b685-2f92b852319e.pdf

CHART 3

Q2 EBITDA margin

Q2 FY2619.3%
Q2 FY2720.4%

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e68bb867-ce7b-4907-b685-2f92b852319e.pdf

CHART 4

Q2 PAT

Q2 FY262,514 INR million
Q2 FY273,251 INR million

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e68bb867-ce7b-4907-b685-2f92b852319e.pdf

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Revenue grew 24.3% YoY

Q2 consolidated operating revenue was 22698 INR million (Q2 FY26) versus 28205 INR million (Q2 FY27). Revenue grew 24.3% YoY.

Watch: Review regional mix

RESEARCH INSIGHT

Operating earnings grew 30.9%

Q2 EBITDA was 4391 INR million (Q2 FY26) versus 5748 INR million (Q2 FY27). Operating earnings grew 30.9%.

Watch: Test margin sustainability

RESEARCH INSIGHT

EBITDA margin expanded 103 bps

Q2 EBITDA margin was 19.3 % (Q2 FY26) versus 20.4 % (Q2 FY27). EBITDA margin expanded 103 bps.

Watch: Reconcile mix and overhead

RESEARCH INSIGHT

PAT grew 29.3%

Q2 PAT was 2514 INR million (Q2 FY26) versus 3251 INR million (Q2 FY27). PAT grew 29.3%.

Watch: Review finance costs

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Quarter ended September 2026 · Stance WATCH · issuer-sourced consolidated/standalone bases noted. Emcure's Q2 FY27 headline is a combination of broad revenue growth and improving EBITDA and PAT margins, but the investor should not overlook increasing debt and acquisition-related payments. Consolidated revenue from operations was INR28,205 million, up 24.3% YoY, EBITDA INR5,748 million, up 30.9%, and PAT INR3,251 million, up 29.3%. WATCH pending proof that stronger operating margins fund investment and borrowings. This is an investment-quality test, not a share-price target or an unsupported estimate of enterprise value. [S1][S2]

Key decision figurePrior periodCurrent period
Q2 consolidated operating revenue22698 INR million (Q2 FY26)28205 INR million (Q2 FY27)
Q2 EBITDA4391 INR million (Q2 FY26)5748 INR million (Q2 FY27)
Q2 EBITDA margin19.3 % (Q2 FY26)20.4 % (Q2 FY27)
Q2 PAT2514 INR million (Q2 FY26)3251 INR million (Q2 FY27)
Q2 gross profit13803 INR million (Q2 FY26)16781 INR million (Q2 FY27)
Q2 gross profit margin60.8 % (Q2 FY26)59.5 % (Q2 FY27)
Domestic Q2 revenue10314 INR million (Q2 FY26)11553 INR million (Q2 FY27)
International Q2 revenue12383 INR million (Q2 FY26)16652 INR million (Q2 FY27)

Six data-driven investor takeaways: Q2 consolidated operating revenue: Revenue grew 24.3% YoY. Q2 EBITDA: Operating earnings grew 30.9%. Q2 EBITDA margin: EBITDA margin expanded 103 bps. Q2 PAT: PAT grew 29.3%. Q2 gross profit: Gross profit improved with revenue. Q2 gross profit margin: Gross margin slipped despite EBITDA growth. This original research text sits under the separate, sourced graphical Investment Briefing, and the source identifiers remain privately encoded in the report's provenance record.

Chapter 1 — Investor decision and valuation requirements

Emcure's Q2 FY27 headline is a combination of broad revenue growth and improving EBITDA and PAT margins, but the investor should not overlook increasing debt and acquisition-related payments. Consolidated revenue from operations was INR28,205 million, up 24.3% YoY, EBITDA INR5,748 million, up 30.9%, and PAT INR3,251 million, up 29.3%. WATCH pending proof that stronger operating margins fund investment and borrowings. This is an investment-quality test, not a share-price target or an unsupported estimate of enterprise value. [S1][S2]

Factual tests for the investment case

  • Q2 consolidated operating revenue: 28205 INR million (Q2 FY27) versus 22698 INR million (Q2 FY26). Revenue grew 24.3% YoY; Review regional mix. [S2]
  • Q2 EBITDA: 5748 INR million (Q2 FY27) versus 4391 INR million (Q2 FY26). Operating earnings grew 30.9%; Test margin sustainability. [S2]
  • Q2 EBITDA margin: 20.4 % (Q2 FY27) versus 19.3 % (Q2 FY26). EBITDA margin expanded 103 bps; Reconcile mix and overhead. [S2]

What this means for the next reporting period. Revenue grew 24.3% YoY. A substantive follow-up is to review regional mix. Operating earnings grew 30.9%. A substantive follow-up is to test margin sustainability. EBITDA margin expanded 103 bps. A substantive follow-up is to reconcile mix and overhead. Management goals, future launches, announced capacity and unearned cash inflows are not booked as realized revenue or profit. The periods, currencies, reported and adjusted accounting labels must be held constant when recomputing growth.

Chapter 2 — Reported Q2 and H1 and quality of earnings

The issuer's consolidated P&L reports Q2 gross profit INR16,781 million versus INR13,803 million, with gross profit margin declining to 59.5% from 60.8%. EBITDA nonetheless expanded faster than revenue, lifting EBITDA margin to 20.4% from 19.3%. PBT grew to INR4,459 million from INR3,414 million, and PAT increased to INR3,251 million from INR2,514 million; effective tax rate was 27.1% against 26.4%. H1 revenue INR54,009 million, EBITDA INR10,828 million and PAT INR6,176 million are six-month values and should not be compared directly with quarterly figures. [S1][S2]

Factual tests for the investment case

  • Q2 EBITDA margin: 20.4 % (Q2 FY27) versus 19.3 % (Q2 FY26). EBITDA margin expanded 103 bps; Reconcile mix and overhead. [S2]
  • Q2 PAT: 3251 INR million (Q2 FY27) versus 2514 INR million (Q2 FY26). PAT grew 29.3%; Review finance costs. [S2]
  • Q2 gross profit: 16781 INR million (Q2 FY27) versus 13803 INR million (Q2 FY26). Gross profit improved with revenue; Track input yields. [S2]

What this means for the next reporting period. EBITDA margin expanded 103 bps. A substantive follow-up is to reconcile mix and overhead. PAT grew 29.3%. A substantive follow-up is to review finance costs. Gross profit improved with revenue. A substantive follow-up is to track input yields. Management goals, future launches, announced capacity and unearned cash inflows are not booked as realized revenue or profit. The periods, currencies, reported and adjusted accounting labels must be held constant when recomputing growth.

Chapter 3 — Products, therapeutic / operating segments and channels

Domestic Q2 operations generated INR11,553 million revenue against INR10,314 million last Q2, with growth led by women's health, cardio-metabolic and CNS demand. International operations generated INR16,652 million compared with INR12,383 million, growing 34.5% YoY. Europe produced INR6,043 million, rest of world INR6,297 million and Canada INR4,312 million in Q2; these markets have different product approval schedules, currency exposure, distributor economics and channel concentration. Mix improvements cannot be inferred solely from absolute international growth without comparable gross margins. [S1][S2]

Factual tests for the investment case

  • Q2 gross profit: 16781 INR million (Q2 FY27) versus 13803 INR million (Q2 FY26). Gross profit improved with revenue; Track input yields. [S2]
  • Q2 gross profit margin: 59.5 % (Q2 FY27) versus 60.8 % (Q2 FY26). Gross margin slipped despite EBITDA growth; Inspect product composition. [S2]
  • Domestic Q2 revenue: 11553 INR million (Q2 FY27) versus 10314 INR million (Q2 FY26). Domestic market grew 12%; Observe therapy launches. [S2]

What this means for the next reporting period. Gross profit improved with revenue. A substantive follow-up is to track input yields. Gross margin slipped despite EBITDA growth. A substantive follow-up is to inspect product composition. Domestic market grew 12%. A substantive follow-up is to observe therapy launches. Management goals, future launches, announced capacity and unearned cash inflows are not booked as realized revenue or profit. The periods, currencies, reported and adjusted accounting labels must be held constant when recomputing growth.

Chapter 4 — Management execution and analyst Q&A challenges

Management highlighted launches and execution across UK/EU, Canadian market-share gains, and non-ARV launches in Latin America, CIS, Asia and Africa. The presentation referred to a Canada pipeline exceeding 50 products, recent approval milestones including liposomal amphotericin B in Brazil/Mexico and an ARV program with lenacapavir filing. These are product/regulatory and commercial milestones, not assurance of near-term revenue or a particular margin. Analysts should question launch timing, distribution partners, product-specific yields and patent/regulatory timelines. [S1][S2]

Factual tests for the investment case

  • Domestic Q2 revenue: 11553 INR million (Q2 FY27) versus 10314 INR million (Q2 FY26). Domestic market grew 12%; Observe therapy launches. [S2]
  • International Q2 revenue: 16652 INR million (Q2 FY27) versus 12383 INR million (Q2 FY26). International operations grew 34.5%; Track currency and regulatory mix. [S2]
  • H1 operating revenue: 54009 INR million (H1 FY27) versus 43704 INR million (H1 FY26). Six-month revenue grew 23.6%; Check H2 order quality. [S2]

What this means for the next reporting period. Domestic market grew 12%. A substantive follow-up is to observe therapy launches. International operations grew 34.5%. A substantive follow-up is to track currency and regulatory mix. Six-month revenue grew 23.6%. A substantive follow-up is to check h2 order quality. Management goals, future launches, announced capacity and unearned cash inflows are not booked as realized revenue or profit. The periods, currencies, reported and adjusted accounting labels must be held constant when recomputing growth.

Chapter 5 — Cash generation, capex, debt and asset payback

Consolidated balance sheet borrowings increased to INR14,673 million at September 2026 from INR12,041 million in March 2026, while cash and bank balances were INR1,502 million against INR1,475 million. Management reported net debt INR13,171 million and described Gennova/Mantra consolidation and earnout payments.

Despite this, the issuer's H1 cash-flow summary showed net cash from operations INR7,235 million versus INR2,562 million in H1 FY26; capex was INR2,877 million versus INR1,700 million. Cash generation and debt movements must be reconciled with M&A, not treated as contradictory or as an automatic sign of excess unencumbered cash. [S1][S2]

Factual tests for the investment case

  • H1 operating revenue: 54009 INR million (H1 FY27) versus 43704 INR million (H1 FY26). Six-month revenue grew 23.6%; Check H2 order quality. [S2]
  • H1 EBITDA: 10828 INR million (H1 FY27) versus 8430 INR million (H1 FY26). Half-year EBITDA increased 28.6%; Monitor cost discipline. [S2]
  • H1 net cash from operations: 7235 INR million (H1 FY27) versus 2562 INR million (H1 FY26). Operating cash improved substantially; Reconcile inventory and receivables. [S2]

What this means for the next reporting period. Six-month revenue grew 23.6%. A substantive follow-up is to check h2 order quality. Half-year EBITDA increased 28.6%. A substantive follow-up is to monitor cost discipline. Operating cash improved substantially. A substantive follow-up is to reconcile inventory and receivables. Management goals, future launches, announced capacity and unearned cash inflows are not booked as realized revenue or profit. The periods, currencies, reported and adjusted accounting labels must be held constant when recomputing growth.

Chapter 6 — Conditional bull/base/bear scenarios and falsifiers

The upside scenario requires sustained 24%-plus sales momentum, international launch conversion, EBITDA margin resilience around 20.4% and strong cash generation after expansion. A base case has domestic and export growth but a more modest margin path as newer products and debt finance costs rise. A bear case includes pricing pressure, regulatory delays, unexpected product quality constraints or higher acquisition-related payouts that reduce after-tax returns. Neither management's pipeline nor observed gross revenue establishes valuation without current share price and capital structure. [S1][S2]

Factual tests for the investment case

  • Q2 consolidated operating revenue: 28205 INR million (Q2 FY27) versus 22698 INR million (Q2 FY26). Revenue grew 24.3% YoY; Review regional mix. [S2]
  • Q2 EBITDA: 5748 INR million (Q2 FY27) versus 4391 INR million (Q2 FY26). Operating earnings grew 30.9%; Test margin sustainability. [S2]
  • Q2 EBITDA margin: 20.4 % (Q2 FY27) versus 19.3 % (Q2 FY26). EBITDA margin expanded 103 bps; Reconcile mix and overhead. [S2]

What this means for the next reporting period. Revenue grew 24.3% YoY. A substantive follow-up is to review regional mix. Operating earnings grew 30.9%. A substantive follow-up is to test margin sustainability. EBITDA margin expanded 103 bps. A substantive follow-up is to reconcile mix and overhead. Management goals, future launches, announced capacity and unearned cash inflows are not booked as realized revenue or profit. The periods, currencies, reported and adjusted accounting labels must be held constant when recomputing growth.

Chapter 7 — Quarterly investor action plan and monitoring

The investor action remains WATCH until management reports another period of comparable mix and collection performance. Monitor the Q2 revenue INR28,205 million, EBITDA INR5,748 million, PAT INR3,251 million, and gross profit margin 59.5% for evidence of profitable scale. Reconcile domestic INR11,553 million versus international INR16,652 million, and check H1 operating cash INR7,235 million against capex INR2,877 million and rising borrowings. A stronger stance needs stable margins and cash after M&A; regulatory or cash-conversion setbacks are warning signs. [S1][S2]

Factual tests for the investment case

  • Q2 EBITDA margin: 20.4 % (Q2 FY27) versus 19.3 % (Q2 FY26). EBITDA margin expanded 103 bps; Reconcile mix and overhead. [S2]
  • Q2 PAT: 3251 INR million (Q2 FY27) versus 2514 INR million (Q2 FY26). PAT grew 29.3%; Review finance costs. [S2]
  • Q2 gross profit: 16781 INR million (Q2 FY27) versus 13803 INR million (Q2 FY26). Gross profit improved with revenue; Track input yields. [S2]

What this means for the next reporting period. EBITDA margin expanded 103 bps. A substantive follow-up is to reconcile mix and overhead. PAT grew 29.3%. A substantive follow-up is to review finance costs. Gross profit improved with revenue. A substantive follow-up is to track input yields. Management goals, future launches, announced capacity and unearned cash inflows are not booked as realized revenue or profit. The periods, currencies, reported and adjusted accounting labels must be held constant when recomputing growth.

Clickable issuer and exchange filings

[S1] Emcure Pharmaceuticals Limited Q2 FY27 earnings-call transcript — accepted transcript covering management and investor questions about the September quarter. [S2] Emcure Pharmaceuticals Limited Q2 and H1 FY27 investor presentation — financial statements and management operating metrics.

Evidence limitations: Company filings are the research source. Specific valuation multiples, market price, future dividends, share counts or debt forecasts are omitted when not supported by these documents. Management guidance and the issuer's adjusted figures must not be mistaken for statutory earnings, or for independently certified cash flow.

Additional company evidence

CHART 5

Q2 gross profit

Q2 FY2613,803 INR million
Q2 FY2716,781 INR million

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e68bb867-ce7b-4907-b685-2f92b852319e.pdf

CHART 6

Q2 gross profit margin

Q2 FY2660.8%
Q2 FY2759.5%

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e68bb867-ce7b-4907-b685-2f92b852319e.pdf

CHART 7

Domestic Q2 revenue

Q2 FY2610,314 INR million
Q2 FY2711,553 INR million

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e68bb867-ce7b-4907-b685-2f92b852319e.pdf

CHART 8

International Q2 revenue

Q2 FY2612,383 INR million
Q2 FY2716,652 INR million

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e68bb867-ce7b-4907-b685-2f92b852319e.pdf

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure
  2. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.